🔎 Trials Near Me

Akèy › Limfòm folikilè › Washington › Seattle

Etid klinik pou Limfòm folikilè nan Seattle, WA

15 etid pou Limfòm folikilè ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Ap rekriteFaz 1/2
  • Research Site, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Ap rekriteFaz 1/2
  • Fred Hutchinson Cancer Research Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Ap rekriteFaz 1
  • University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Ap rekriteFaz 1
  • Swedish Cancer Institute (SCI), Seattle
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Ap rekriteFaz 3
  • Fred Hutch Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT05303519

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Ap rekriteFaz 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06442475

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Ap rekriteFaz 1
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT07121946

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Ap rekriteFaz 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT06948786

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Ap rekriteFaz 2Volontè an sante akeyi
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months · Tout sèks · Mizajou May 29, 2026 · NCT04195633

Study of SGR-1505 in Mature B-Cell Neoplasms

Ap rekriteFaz 1
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Ap rekriteFaz 1/2
  • University of Washington-Seattle Cancer Care Alliance, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Jan 30, 2026 · NCT04669171

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Ap rekriteEtid obsèvasyon
  • Massive Bio SYNERGY-AI site, Seattle
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Ap rekriteFaz 1
  • Swedish Cancer Institute, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2025 · NCT05780034

Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients

Ap rekrite
  • University of Washington Medical Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Feb 23, 2021 · NCT02537769

Etid Limfòm folikilè nan lòt vil

Lòt etid nan Seattle

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.